6 research outputs found
Comparing biological markers of Alzheimer\u27s disease across blood fraction and platforms: Comparing apples to oranges
Introduction: This study investigated the comparability of potential Alzheimer\u27s disease (AD) biomarkers across blood fractions and assay platforms. Methods: Nonfasting serum and plasma samples from 300 participants (150 AD patients and 150 controls) were analyzed. Proteomic markers were obtained via electrochemiluminescence or Luminex technology. Comparisons were conducted via Pearson correlations. The relative importance of proteins within an AD diagnostic profile was examined using random forest importance plots. Results: On the Meso Scale Discovery multiplex platform, 10 of the 21 markers shared \u3e50% of the variance across blood fractions (serum amyloid A R2 = 0.99, interleukin (IL)10 R2 = 0.95, fatty acid-binding protein (FABP) R2 = 0.94, I309 R2 = 0.94, IL-5 R2 = 0.94, IL-6 R2 = 0.94, eotaxin3 R2 = 0.91, IL-18 R2 = 0.87, soluble tumor necrosis factor receptor 1 R2 = 0.85, and pancreatic polypeptide R2 = 0.81). When examining protein concentrations across platforms, only five markers shared \u3e50% of the variance (beta 2 microglobulin R2 = 0.92, IL-18 R2 = 0.80, factor VII R2 = 0.78, CRP R2 = 0.74, and FABP R2 = 0.70). Discussion: The current findings highlight the importance of considering blood fractions and assay platforms when searching for AD relevant biomarkers
A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of ÎČ-amyloid load in an AD cohort
Alzheimer\u27s Disease (AD) is the most common form of dementia, characterised by extracellular amyloid deposition as plaques and intracellular neurofibrillary tangles of tau protein. As no current clinical test can diagnose individuals at risk of developing AD, the aim of this project is to evaluate a blood-based biomarker panel to identify individuals who carry this risk. We analysed the levels of 22 biomarkers in clinically classified healthy controls (HC), mild cognitive impairment (MCI) and Alzheimer\u27s participants from the well characterised Australian Imaging, Biomarker and Lifestyle (AIBL) study of aging. High levels of IL-10 and IL-12/23p40 were significantly associated with amyloid deposition in HC, suggesting that these two biomarkers might be used to detect at risk individuals. Additionally, other biomarkers (Eotaxin-3, Leptin, PYY) exhibited altered levels in AD participants possessing the APOE ϔ4 allele. This suggests that the physiology of some potential biomarkers may be altered in AD due to the APOE ϔ4 allele, a major risk factor for AD. Taken together, these data highlight several potential biomarkers that can be used in a blood-based panel to allow earlier identification of individuals at risk of developing AD and/or early stage AD for which current therapies may be more beneficial
A Depressive Endophenotype Of Poorer Cognition Among Cognitively Healthy Community-dwelling Adults: Results From The Western Australia Memory Study
Objective: The objective was to evaluate in a cognitively normal population the utility of an endophenotype of the depressionâcognition link previously shown to be related to cognitive functioning in mild cognitive impairment and Alzheimer\u27s disease. Methods: The data of 460 cognitively normal adults aged 32â92âyears (Mâ=â63.5, standard deviationâ=â9.24) from the Western Australian Memory Study with the Cross-national comparisons of the Cambridge Cognitive Examination-revised (CAMCOG-R) scores and 30-item Geriatric Depression Scale (GDS) scores were analyzed to determine the relationship between the five-item depressive endophenotype (DepE) scale drawn from the GDS and level of performance on a measure of cognitive functioning. Results: For the entire sample, there was a nonsignificant trend toward a negative relationship between DepE and CAMCOG-R scores. When analyzed for those 65âyears and older, there was a significant negative relationship between the two measures (pâ=â0.001) with DepE scores significantly increasing the risk for performing more poorly on the CAMCOG-R (odds ratioâ=â1.53). Analysis of data for those 70âyears and older showed that DepE was the only predictor significantly related to poorer CAMCOG-R performance (pâ=â0.001). For the 70âyears and older group, DepE scores significantly increased the risk of poorer CAMCOG-R scores (odds ratioâ=â2.23). Analysis of the entire sample on the basis of ApoEΔ4 carrier status revealed that DepE scores were significantly negatively related only to ApoEΔ4 noncarrier regardless of age. Conclusions: Elevated DepE scores are associated with poor neuropsychological performance among cognitively normal older adults. Use of the DepE may allow for the identification of a subset of older adults where depression is a primary factor in cognitive decline and who may benefit from antidepressant therapies
Innovative diagnostic tools for early detection of Alzheimer\u27s disease
Current state-of-the-art diagnostic measures of Alzheimer\u27s disease (AD) are invasive (cerebrospinal fluid analysis), expensive (neuroimaging) and time-consuming (neuropsychological assessment) and thus have limited accessibility as frontline screening and diagnostic tools for AD. Thus, there is an increasing need for additional noninvasive and/or cost-effective tools, allowing identification of subjects in the preclinical or early clinical stages of AD who could be suitable for further cognitive evaluation and dementia diagnostics. Implementation of such tests may facilitate early and potentially more effective therapeutic and preventative strategies for AD. Before applying them in clinical practice, these tools should be examined in ongoing large clinical trials. This review will summarize and highlight the most promising screening tools including neuropsychometric, clinical, blood, and neurophysiological tests
Author Correction: Genetic meta-analysis of diagnosed Alzheimer\u27s disease identifies new risk loci and implicates AÎČ, tau, immunity and lipid processing.
An amendment to this paper has been published and can be accessed via a link at the top of the paper